[**J. David Giese**](https://www.linkedin.com/in/jdavidgiese/overlay/about-this-profile/?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base%3BPHIy57C%2BRSCCc3D%2FByrW6Q%3D%3D)

1st degree connection

Rapid, fixed-price FDA software and cyber docs for 510(k)s

*
* Innolitics
*
* Boston University

New York, New York, United States  [Contact info](https://www.linkedin.com/in/jdavidgiese/overlay/contact-info/)

The [FDA](https://www.linkedin.com/company/fda/) requires SBOMs in premarket submissions — but most teams treat them as a checkbox. That's a mistake. ❌

A well-structured SBOM does more than list your dependencies. It signals to FDA that you understand your software supply chain and have a plan for monitoring it post-market.

Six practices that separate strong submissions from deficient ones:
→ Automate generation in your CI/CD pipeline — manual SBOMs go stale the moment dependencies change
→ Include software metadata beyond component lists — company name, contact, git hash, timestamp
→ Cover every NTIA baseline field, plus FDA's additions: level of support and end-of-support date
→ Continuously monitor vulnerabilities in the field, not just at submission time
→ Provide both human-readable and machine-readable versions — JSON alone doesn't cut it
→ Periodically review vulnerabilities for patient safety impact, not just logging

One detail teams miss: in August 2024, FDA pushed back on email-only SBOM distribution. SBOMs must be readily available to end users at all times as part of device labeling.

I wrote a full guide with FAQs, field-by-field examples, and common mistakes: [https://hubs.ly/Q047bwK10](https://hubs.ly/Q047bwK10)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[\#Cybersecurity](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23sbom&origin=HASH_TAG_FROM_FEED)
[\#SBOM](https://www.linkedin.com/search/results/all/?keywords=%23sbom&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23softwarebillofmaterials&origin=HASH_TAG_FROM_FEED)
[\#SoftwareBillOfMaterials](https://www.linkedin.com/search/results/all/?keywords=%23softwarebillofmaterials&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevicesoftware&origin=HASH_TAG_FROM_FEED)
[\#MedicalDeviceSoftware](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevicesoftware&origin=HASH_TAG_FROM_FEED)

Who is the "legal Manufacturer" — and where does the DHF live when the [FDA](https://www.linkedin.com/company/fda/) shows up?

This question comes up in almost every SaMD partnership where one company builds the algorithm and another (like [Innolitics](https://www.linkedin.com/company/innolitics/)) brings the device to market.

The legal Manufacturer is the entity that introduces the finished device into US commercial distribution. They take responsibility for the device's intended use, labeling, and regulatory compliance. They register and list the device. They're the ones subject to FDA inspection.

Algorithm or software component developers don't need to independently register and list. They can be controlled as critical suppliers within the Manufacturer's QMS.

Q: What about the design history file?
A: Portions of the DHF can reside at critical suppliers. This is explicitly allowed under 21 CFR 820.30(j): "The DHF shall contain or reference the records necessary to demonstrate that the design was developed in accordance with the approved design plan and the requirements of this part."

The key word is "reference." The Manufacturer is still responsible and accountable for the completeness and adequacy of the entire DHF — but they don't have to physically house every record.

Best practice:
→ Manufacturer maintains the DHF master index, owns system-level records, references supplier-controlled records, and approves sub-component design outputs and changes
→ Supplier maintains detailed software component DHF elements, provides controlled access, and supports audits and FDA inspections contractually via a Quality Agreement

When FDA inspects, the manufacturer either produces supplier-held records directly or facilitates access (often remote) to the supplier who can provide them.

If you're structuring a SaMD partnership right now, get the Quality Agreement and DHF access protocols in place early. It's much easier to set up before a 483 than after one.

We help SaMD companies set up and maintain QMS frameworks designed for exactly these kinds of manufacturer-supplier structures: [https://hubs.li/Q0470bTb0](https://hubs.li/Q0470bTb0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23qms&origin=HASH_TAG_FROM_FEED)
[\#QMS](https://www.linkedin.com/search/results/all/?keywords=%23qms&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevice&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevice](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevice&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)

🐌 Can Your Software Diagrams Slow Down Your FDA Submission?

The [FDA](https://www.linkedin.com/company/fda/)'s cybersecurity guidance (most recently updated Feb 2026\) asks manufacturers for detailed diagrams and a system-level traceability and analysis inclusive of end-to-end security analyses of all the communications in the medical device system of their premarket submission. This means FDA reviewers need to be able to trace every communication path showing how data, code, and commands are protected between any two assets in the system.

Each security architecture view requires detailed asset identification, labeled communication paths with protocol specifics, cryptographic methods, access controls, and precise traceability to your risk analysis, test evidence, and SBOM.

That's a lot of diagrams. And here's the problem: If your baseline system and software architecture diagram doesn't clearly distinguish hardware from software items, doesn't label its arrows, and doesn't use consistent IDs that trace to the rest of your documentation — then building the cybersecurity views on top of it is exponentially harder.

You end up reverse-engineering your own system to answer questions your diagrams should have already answered.

The architecture diagram isn't just a submission artifact. It's the foundation that every other piece of documentation builds on — cybersecurity views, risk analysis, test traceability, SBOM mapping.

Get it right the first time, and the cybersecurity documentation writes itself. Get it wrong, and you're possibly looking at Additional Information requests that add months to your timeline.

I wrote about the most common architecture diagram mistakes and how to avoid them: [https://hubs.li/Q046RrJm0](https://hubs.li/Q046RrJm0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[\#Cybersecurity](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23qmsr&origin=HASH_TAG_FROM_FEED)
[\#QMSR](https://www.linkedin.com/search/results/all/?keywords=%23qmsr&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23softwarearchitecture&origin=HASH_TAG_FROM_FEED)
[\#SoftwareArchitecture](https://www.linkedin.com/search/results/all/?keywords=%23softwarearchitecture&origin=HASH_TAG_FROM_FEED)

The [FDA](https://www.linkedin.com/company/fda/) is hosting a free town hall on April 1 to walk through the updated inspection process under the new QMSR framework. This is the first public walkthrough of how the new process works.

If you have questions for the panel, email QMSR-Rule@fda.hhs.gov. We discovered all questions must be received by March 16, 2026 to be considered for the discussion.

Here's what stands out from reading the new compliance program:
→ Inspectors use the manufacturer's own risk management documentation to focus the inspection — and review it throughout, not just at one checkpoint
→ For compliance follow-ups, inspectors evaluate the timeliness and depth of corrective actions, whether corrections addressed product already in the field, whether risk management was considered, and whether the fix was scoped across the entire QMS — not just the area where the problem was found

In other words: FDA is auditing your project management discipline, even if they don't call it that.

Medical device timelines slip for three predictable reasons:
→ Unknown work stays hidden until late in the project
→ No single owner is accountable for surfacing uncertainty
→ Tasks are too big to estimate, so dates are guesses that keep moving

We've published our full approach to preventing timeline slips, and encourage reading this before attending the town hall:

𝗞𝗲𝗲𝗽 𝘀𝗽𝗹𝗶𝘁𝘁𝗶𝗻𝗴 𝘁𝗮𝘀𝗸𝘀 𝘂𝗻𝘁𝗶𝗹 𝘁𝗵𝗲𝘆'𝗿𝗲 𝗲𝘀𝘁𝗶𝗺𝗮𝗯𝗹𝗲. If the owner can't answer "How long will this take?", "What is left to do?", and "What inputs do you need before you can start?" — split it further.
𝗢𝗻𝗲 𝗮𝗰𝗰𝗼𝘂𝗻𝘁𝗮𝗯𝗹𝗲 𝗼𝘄𝗻𝗲𝗿 𝗽𝗲𝗿 𝘁𝗮𝘀𝗸. Others can contribute, review, and approve — but one person drives it to completion. Without this, schedule risk stays hidden.
𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝗮𝗯𝗹𝗲𝘀, 𝗻𝗼𝘁 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝗶𝗲𝘀. "Cybersecurity documentation complete" — not "Work on cybersecurity." If the goal is FDA clearance, the eSTAR deliverables are your checklist.
𝗧𝗵𝗲 𝗚𝗮𝗻𝘁𝘁 𝗰𝗵𝗮𝗿𝘁 𝗶𝘀 𝗮 𝗹𝗶𝘃𝗶𝗻𝗴 𝗺𝗼𝗱𝗲𝗹. Run weekly or biweekly reviews where each owner updates completion dates, status, and blockers. Without this cadence, the chart goes stale and loses its value as a forecasting tool.
𝗙𝗼𝗿𝗰𝗲 𝘂𝗻𝗰𝗲𝗿𝘁𝗮𝗶𝗻𝘁𝘆 𝘁𝗼 𝘁𝗵𝗲 𝘀𝘂𝗿𝗳𝗮𝗰𝗲. Once timeline risk is visible, you can optimize — add resources, reduce scope, or push work until after the first submission.

This is the approach [Innolitics](https://www.linkedin.com/company/innolitics/) uses when delivering 510(k) submissions on guaranteed timelines.

Full article: [https://hubs.li/Q046P9cy0](https://hubs.li/Q046P9cy0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23qmsr&origin=HASH_TAG_FROM_FEED)
[\#QMSR](https://www.linkedin.com/search/results/all/?keywords=%23qmsr&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23projectmanagement&origin=HASH_TAG_FROM_FEED)
[\#ProjectManagement](https://www.linkedin.com/search/results/all/?keywords=%23projectmanagement&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23iso13485&origin=HASH_TAG_FROM_FEED)
[\#ISO13485](https://www.linkedin.com/search/results/all/?keywords=%23iso13485&origin=HASH_TAG_FROM_FEED)

3-month FDA review. Zero major deficiencies. AINN response in 6 days.

For context: applicants with 6+ clearances average 130 days from submission to clearance. New applicants average 170 days. This is the result of when a regulatory strategy comes from the software architecture, not around it.

[Neosoma Inc.](https://www.linkedin.com/company/neosoma-inc/)'s first FDA clearance was monolithic: every component submitted as one device. When they needed to clear a second AI indication, the conventional approach would have meant re-submitting the entire platform.

[Innolitics](https://www.linkedin.com/company/innolitics/) saw something different.

Neosoma's platform had functionally independent components: pre-processing, post-processing, PACS integration, UI, and cloud infrastructure were all separate from the segmentation engine. Our deep DICOM expertise let us draw a clean boundary between the PACS integration layer and the CNN model — and defend it to the [FDA](https://www.linkedin.com/company/fda/).

The result:
→ What stayed out of scope: the entire pre-processing pipeline, post-processing, DICOM/PACS workflow, UI, and cloud infrastructure — all already cleared in Neosoma Glioma (K221738)
→ What actually needed clearance: one thing — the new CNN model trained on brain metastases
→ No re-testing pre-processing. No re-validating DICOM workflows. No cybersecurity re-assessment of unchanged components.
→ We flipped the predicate strategy — VBrain (K203235) as primary, Neosoma Glioma as secondary — creating a dual-predicate template reusable for every future indication

The modular approach limiting the cybersecurity scope, dropped the validation effort proportionally, and compressed time to market. This is why regulatory strategy has to come from the software architecture. A purely regulatory-focused firm wouldn't have read Neosoma's CNN architecture and seen the modular opportunity.

If your AI platform is approaching its second or third indication, we've done this before, and are happy to share our strategies with you\!

Full case study → [https://hubs.li/Q046DBQ90](https://hubs.li/Q046DBQ90)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[\#AIinHealthcare](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fdaclearance&origin=HASH_TAG_FROM_FEED)
[\#FDAClearance](https://www.linkedin.com/search/results/all/?keywords=%23fdaclearance&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23dicom&origin=HASH_TAG_FROM_FEED)
[\#DICOM](https://www.linkedin.com/search/results/all/?keywords=%23dicom&origin=HASH_TAG_FROM_FEED)

There's a misconception floating around that agentic AI tools can't be used for medical device development.

Do FDA regulations somehow prohibit agentic AI tools? Can your AI-generated code be validated? How much risk are you undertaking by developing with agentic tools?

[Innolitics](https://www.linkedin.com/company/innolitics/) addresses these questions and more here: [https://hubs.li/Q046gTM20](https://hubs.li/Q046gTM20)

The same principles that make AI work for general software make it work for regulated software: explicit requirements, traceable design decisions, automated verification, rigorous review, continuous cleanup. The mechanics don't change because the stakes are higher.

What does change is the cost of skipping them.

With the QMSR now fully in effect and FDA's new risk-based inspection process replacing QSIT as of February 2, 2026, this is a good moment to pressure-test whether your quality system reflects how your software is actually being built. The [FDA](https://www.linkedin.com/company/fda/) is hosting a free virtual town hall on April 1, 2026 (1–2 PM ET) to walk through exactly what changed.

If you're building medical device software and have questions about agentic AI development, or traditional development, we do both. Reach out — we're happy to talk through what makes sense for your team and your regulatory pathway.

Last week, the [FDA](https://www.linkedin.com/company/fda/)'s Digital Health Center of Excellence (DHCoE) updated its digital health technology transparency lists

→ AI list: [https://hubs.li/Q046cm4q0](https://hubs.li/Q046cm4q0)

→ Sensor-based Digital Health Technology (sDHT) devices: [https://hubs.li/Q046cwWL0](https://hubs.li/Q046cwWL0)

→ Augmented / Virtual Reality (AR/VR) medical devices: [https://hubs.li/Q046crpx0](https://hubs.li/Q046crpx0)

These lists are a useful transparency initiative as they give a concrete snapshot of where digital health innovation is actually reaching FDA authorization

Speaking of digital health transparency tools — the Innolitics 510(k) Browser is listed on FDA's openFDA Community page ([https://hubs.li/Q046cz7R0](https://hubs.li/Q046cz7R0)) as a resource for exploring 510(k) data.

One feature that pairs well with these DHCoE lists: our "Is SaMD" filter lets you isolate software-as-a-medical-device clearances across the full 510(k) database — which is useful if you're tracking SaMD regulatory trends beyond what the curated FDA lists cover.

Check it out yourself here: [https://hubs.li/Q046cz8M0](https://hubs.li/Q046cz8M0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23sdht&origin=HASH_TAG_FROM_FEED)
[\#sDHT](https://www.linkedin.com/search/results/all/?keywords=%23sdht&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23arvr&origin=HASH_TAG_FROM_FEED)
[\#ARVR](https://www.linkedin.com/search/results/all/?keywords=%23arvr&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23openfda&origin=HASH_TAG_FROM_FEED)
[\#openFDA](https://www.linkedin.com/search/results/all/?keywords=%23openfda&origin=HASH_TAG_FROM_FEED)

AI coding tools are making it faster than ever to build healthtech prototypes. Claude Code, Cursor, Copilot — you can go from idea to working demo in days.

But speed doesn't change what the [FDA](https://www.linkedin.com/company/fda/) expects in your cybersecurity documentation.

We've reviewed dozens of FDA AINN (additional information) letters, and the same cybersecurity deficiencies show up repeatedly:
→ Incomplete threat modeling that misses insider threats and supply chain risks
→ Missing or vague authentication and authorization controls
→ No SBOM, or an SBOM that omits OTS and open-source components
→ Weak encryption documentation without algorithm justification
→ No clear timelines for patch management and security updates

These are not edge cases\! These are deficiencies that put your 510(k), De Novo, or PMA on hold.

Most teams invest heavily in building the software. Fewer invest the same rigor in the cybersecurity documentation FDA actually reviews — threat models, SBOMs, pen test reports, and patch management plans.

We compiled the 14 most common FDA cybersecurity deficiencies from real AINN letters, with best practices for addressing each one:
\--\> [https://hubs.li/Q0461cj90](https://hubs.li/Q0461cj90)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[\#Cybersecurity](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23healthtech&origin=HASH_TAG_FROM_FEED)
[\#HealthTech](https://www.linkedin.com/search/results/all/?keywords=%23healthtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23sbom&origin=HASH_TAG_FROM_FEED)
[\#SBOM](https://www.linkedin.com/search/results/all/?keywords=%23sbom&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23ainn&origin=HASH_TAG_FROM_FEED)
[\#AINN](https://www.linkedin.com/search/results/all/?keywords=%23ainn&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23holdletter&origin=HASH_TAG_FROM_FEED)
[\#HoldLetter](https://www.linkedin.com/search/results/all/?keywords=%23holdletter&origin=HASH_TAG_FROM_FEED)

Does FDA require SaMD manufacturers to use software escrow for their key vendors?

Not necessarily. But software escrow can be an important security risk control if you rely on closed-source, hard-to-replace third-party components.

Consider the following sequence of events:

1\. Your SaMD uses a closed-source third-party component that’s difficult to replace

2\. The vendor goes out of business, is acquired, or discontinues the product

3\. A vulnerability is discovered in the dependency

4\. You can’t patch quickly (or can’t replace the component fast enough)

5\. Threat actor exploits the vulnerability in your device

Putting key materials in escrow can mitigate this risk. If the vendor stops supporting the product, an escrow agent can release what you need so your team (or a third party you hire) can maintain, patch, or rebuild the component to protect patients and users.

For SaMD, it’s usually not enough to escrow only source code. To be useful, escrow often needs build instructions, pinned dependencies, build containers, and test artifacts. For AI/ML components, it may also include model artifacts and the training pipeline (or a workable substitute).

Have you ever needed to put a vendor’s source code in escrow? If so, did you find any escrow vendors particularly good?

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[\#Cybersecurity](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)

🔔 A TON of highly anticipated De Novo summaries just dropped. One that you have been waiting for might be on the list.

Here are the top 9, with a link to the first device that established each one purely software-focused (SaMD) or clinical AI/ML product codes established via De Novo that are most relevant to the Innolitics audience.

\-\> SGB — Pain Assessment Software In Non-Communicative Adults (PainChek) — Granted 10/06/2025 — [https://hubs.li/Q045mtts0](https://hubs.li/Q045mtts0)

\-\> SFH — Pathology Software Algorithm Analyzing Digital Images For Cancer Prognosis (ArteraAI Prostate ) — Granted 07/31/2025 — [https://hubs.li/Q045mvKN0](https://hubs.li/Q045mvKN0)

\-\> SEZ — Radiological Software Device To Predict Future Breast Cancer Risk (Allix5 ) — Granted 05/30/2025 — [https://hubs.li/Q045mtvd0](https://hubs.li/Q045mtvd0)

\-\> SEE — Computerized Behavioral Therapy Device For Migraine (CT-132 ) — Granted 04/11/2025 — [https://hubs.li/Q045mslr0](https://hubs.li/Q045mslr0)

\-\> SBC — Dental Image Analyzer (DentalMonitoring ) — Granted 05/17/2024 — [https://hubs.li/Q045mszr0](https://hubs.li/Q045mszr0)

\-\> SAK — Software Device To Aid In The Prediction Or Diagnosis Of Sepsis (Sepsis ImmunoScore ) — Granted 04/02/2024 — [https://hubs.li/Q045mwh70](https://hubs.li/Q045mwh70)

\-\> SAL — Device, Automated Cell Locating, Bone Marrow (Scopio X100 ) — Granted 03/22/2024 — [https://hubs.li/Q045mvrb0](https://hubs.li/Q045mvrb0)

\-\> QZW — Over-The-Counter Device To Assess Risk Of Sleep Apnea (Samsung Sleep Apnea Feature ) — Granted 02/06/2024 — [https://hubs.li/Q045mtfk0](https://hubs.li/Q045mtfk0)

\-\> QYV — Digital Cervical Cytology Slide Imaging System With AI Algorithm (Hologic Genius ) — Granted 01/31/2024 — [https://hubs.li/Q045mw0n0](https://hubs.li/Q045mw0n0)

Each new product code represents a new frontier for medical technology. If you're developing a novel device and think you might have a De Novo on your hands, navigating the process is key.

Check out our guide on De Novo requests for more info: [https://hubs.li/Q045mvBq0](https://hubs.li/Q045mvBq0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23denovo&origin=HASH_TAG_FROM_FEED)
[\#DeNovo](https://www.linkedin.com/search/results/all/?keywords=%23denovo&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[\#AIinHealthcare](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatory&origin=HASH_TAG_FROM_FEED)
[\#Regulatory](https://www.linkedin.com/search/results/all/?keywords=%23regulatory&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevice&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevice](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevice&origin=HASH_TAG_FROM_FEED)

🏥If you’re building AI/ML medical device software, this is the single most important regulatory signal of 2026\.

On February 17, 2026, the Senate HELP Committee released "Patients and Families First: Building the [FDA](https://www.linkedin.com/company/fda/) of the Future"

What this means for your regulatory strategy:

→ The Senate calls PCCPs "tremendous potential." Pre-approve your testing protocols. Deploy. Monitor. Iterate. This is the framework that makes generative AI regulation viable.
→ Post-market surveillance is shifting from stick to carrot. Companies that build real-world evidence infrastructure into their product—"as core architecture, not afterthought"—should get reduced pre-market burden.
→ The traditional pre-market paradigm fails for generative AI. "You can't pre-validate every possible output of a non-deterministic system." The Senate is connecting generative AI governance to dynamic risk classification based on real-world evidence.

For teams planning submissions now: This creates tailwinds, but doesn't change what you need to do today. Your study designs, clinical validation strategy, and documentation quality still determine whether you clear in 90 days or 200+.

We analyzed the full Senate report and mapped the practical implications → [https://hubs.li/Q044Sf330](https://hubs.li/Q044Sf330)

If your team is building AI-powered medical device software and you want to understand what the Senate's regulatory signal means for your roadmap, let's talk.

We've been mapping this landscape for years, and the frameworks and pathways are published. Book time with us and we'll walk you through where you stand and the options ahead.

Technical debt used to be a low-grade, chronic pain. Now it's an acute tax on every feature you build. Every piece of duplicated logic, every undocumented behavior, every gnarly branching statement becomes a trap for the AI. More rework. More bugs. All of this results in slower delivery\!

The types of debt that are especially toxic:

• Undocumented/Tribal-Knowledge Code: When the person who wrote it is gone, intent is gone too. AI can’t interview past engineers. If it isn’t written down (docs, tests, explicit interfaces), the safest change becomes expensive. The AI can't know what the code should do, only what it does. If behavior isn't documented or tested, the AI will break it.
• Hidden Side Effects: Functions that modify state in unexpected ways are a nightmare to debug, for humans and AI alike.
• Deep Nesting: Code that's hard to read is hard for AI to extend correctly.
• Inconsistent Patterns: If there are five ways to do the same thing, the AI will invent a sixth.
• Missing tests: You can’t possibly remember every single business logic so you rely on tests to remind you of logic that passes or fails after the change. AI is very good at picking up testing failures and fixing them, but it is poor at predicting business logic failures and divergence in failures without tasks already in place

When AI tools hit a bad codebase, the promised productivity gains don't just fail to show up. They reverse. Your velocity collapses under the weight of cleaning up the AI's well-intentioned mistakes.

The teams that succeed with AI will be the ones that build tight feedback systems where humans catch debt before it spirals and continuously course-correct the AI's output.

If you're trying to build safe and effective medical device software, the stakes are even higher. You need a team that understands both sides: what makes code AI-friendly and what makes it FDA-friendly. We've spent 14 years and 100+ device clearances learning exactly that at [Innolitics](https://www.linkedin.com/company/innolitics/).

Whether you need us to build your device software, get you FDA cleared, transform your existing team into an AI-native operation, or all the above, we can help.

Learn more about our approaches to AI-augmented engineering: [https://hubs.li/Q044jJJs0](https://hubs.li/Q044jJJs0)

The [FDA](https://www.linkedin.com/company/fda/) now offers Early Orientation Meetings for software device submissions, but most sponsors don't know when or how to use them.

We asked the FDA for clarification and here's what we learned:

→ Timing: These happen AFTER you submit your 510(k), De Novo, or PMA—during the first few weeks of review

→ Purpose: 30-60 minute device demo and Q\&A to help the review team understand your software, not to get specific feedback on your submission

→ How to request: Include it in your cover letter or email your lead FDA reviewer
once assigned \*\*Key limitation: Not available for Special 510(k)s

This is different from Q-Sub (Pre-Submission) meetings, which happen before you submit and focus on getting FDA feedback on regulatory strategy and study design.

We used this process with RadUnity, a DICOM workflow engine for CT image processing. The Early Orientation Meeting helped the FDA review team understand the automated mapping and image-processing functionality, likely contributing to clearance in \< 70 days from submission.

If you're submitting AI/ML or novel software functions, this could help your review team understand your device faster.

Read about the full RadUnity regulatory strategy: [https://hubs.li/Q042M0n10](https://hubs.li/Q042M0n10)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryStrategy](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevicesoftware&origin=HASH_TAG_FROM_FEED)
[\#MedicalDeviceSoftware](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevicesoftware&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)

Source: [https://hubs.li/Q042LX4j0](https://hubs.li/Q042LX4j0)

Every week at Innolitics, our engineering and regulatory teams hold "10x time" to discuss the most common questions from our client work.

Last week we discussed the difference between PAS vs. 522 Postmarket Surveillance Studies.

Post-Approval Study (PAS)
→ Planned before PMA approval, conducted after
→ Gathers long-term safety and effectiveness data
→ Required as a condition of approval
→ PMA devices only
→ Failure to complete can affect your PMA status

522 Postmarket Surveillance Study
→ FDA-initiated after a device is already on the market
→ Addresses unanticipated or emerging safety concerns
→ Ordered by FDA under Section 522 of the FD\&C Act
→ Applies to Class II or III devices (PMA, 510(k), De Novo)
→ Mandatory with reporting deadlines (typically 3-5 years)

For SaMD companies: While the [FDA](https://www.linkedin.com/company/fda/)'s 522 authority has historically focused on hardware devices (duodenoscopes for CRE infection outbreaks, infusion pumps for dosing errors, metal-on-metal hip implants for revision monitoring), the regulatory landscape is shifting for software devices.

FDA guidance now recognizes 522 studies as appropriate use cases for Real-World Data and Real-World Evidence (RWD/RWE). They no longer need to be fully prospective, site-intensive, or trial-like in the traditional sense. This is particularly significant for AI/ML SaMD, where efficient real-world data collection can replace traditional hardware surveillance approaches.

The PAS is proactive and built into your approval strategy. 522 studies are post-market FDA requirements that demand dedicated resources—understanding this early can prevent surprises.

Not sure if your device could face PAS or 522 requirements? Let's talk strategy, sign up here: [https://hubs.li/Q042xRfz0](https://hubs.li/Q042xRfz0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryStrategy](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23postmarketsurveillance&origin=HASH_TAG_FROM_FEED)
[\#PostMarketSurveillance](https://www.linkedin.com/search/results/all/?keywords=%23postmarketsurveillance&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23pma&origin=HASH_TAG_FROM_FEED)
[\#PMA](https://www.linkedin.com/search/results/all/?keywords=%23pma&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23aihealthcare&origin=HASH_TAG_FROM_FEED)
[\#AIHealthcare](https://www.linkedin.com/search/results/all/?keywords=%23aihealthcare&origin=HASH_TAG_FROM_FEED)

Are you building an AI/ML-enabled neurology diagnostic device? We have some interesting facts for you:

Predetermined Change Control Plans are a new regulatory tool that allow companies to “pre-clear” certain changes within a 510(k), De Novo, or PMA. Of the 6 most recent AI/ML neurology diagnostic devices cleared in 2025, only 2 included a PCCP:

• [Ceribell │ AI-Powered Point-of-Care EEG](https://www.linkedin.com/company/ceribell/) Infant Seizure Detection Software – Deep learning for EEG seizure detection in infants
• [Nox Medical](https://www.linkedin.com/company/nox-medical/) DeepRESP v2.0 – AI and rule-based models for sleep study analysis
• [Brain Electrophysiology Laboratory](https://www.linkedin.com/company/braincompany/) NEAT 001 – Machine learning for automatic sleep staging from EEG
• [Holberg EEG AS, a Natus company](https://www.linkedin.com/company/holberg-eeg-as/) autoSCORE V2.0.0 – Deep learning AI model for EEG abnormality detection
• [Cognoa](https://www.linkedin.com/company/cognoa/) Canvas Dx – Machine learning for autism spectrum disorder diagnosis aid
• [LVIS](https://www.linkedin.com/company/lvis/) NeuroMatch – Deep learning for EEG source localization in epilepsy

Unlike radiology (where FDA reviewers see high volumes of AI/ML submissions and are fluent in ML architectures, training/test splits, and performance benchmarking), neurology panels see fewer AI/ML devices.

Panels with less AI/ML experience tend to be more conservative with PCCPs. The administrative overhead is already high for these new regulatory tools, but it's even higher when you're working with reviewers who need more foundational education about your algorithm.

Predetermined Change Control Protocols work best when:

→ You have well-understood, repeatable changes you plan to make multiple times
→ Each change would otherwise require a separate 510(k) submission
→ You can define precise acceptance criteria and validation protocols upfront
→ Your documentation educates reviewers on ML fundamentals without assuming prior AI/ML fluency
→ The changes stay within your original intended use

Best practices for PCCPs in low-AI-volume panels:

→ Expect to provide more detail than you would for radiology devices
→ Translate ML concepts into clinical language the panel will understand
→ Consider a separate Pre-Sub specifically for your PCCP to gauge panel comfort level
→ If the PCCP adds relatively little value, it may not be worth the extra scrutiny yet

Your submission needs to educate, not just demonstrate. You need reviewers to understand not just \*what\* your algorithm does, but \*how\* and \*why\* it's safe to modify it within your planned parameters.
\---
We specialize in translating complex ML architectures into FDA-ready documentation that panels with limited AI/ML experience can confidently review. Whether you need a PCCP or standard change control, we help you navigate review divisions where AI fluency varies:

Read more here: [https://hubs.li/Q042nH4\_0](https://hubs.li/Q042nH4_0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryStrategy](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23pccp&origin=HASH_TAG_FROM_FEED)
[\#PCCP](https://www.linkedin.com/search/results/all/?keywords=%23pccp&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[\#AIinHealthcare](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23neurology&origin=HASH_TAG_FROM_FEED)
[\#Neurology](https://www.linkedin.com/search/results/all/?keywords=%23neurology&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23d&origin=HASH_TAG_FROM_FEED)
[\#D](https://www.linkedin.com/search/results/all/?keywords=%23d&origin=HASH_TAG_FROM_FEED)…

The [FDA](https://www.linkedin.com/company/fda/) just updated their Premarket Cybersecurity Guidance (February 3, 2026\) to align with the new QMSR regulations.

This new one supersedes the June 2025 version—a rapid 7-month update driven entirely by the QMSR transition.

At [Innolitics](https://www.linkedin.com/company/innolitics/), we track of the latest changes to key regulatory guidance so that you don't have to keep up with what matters to you. We help medical device manufacturers secure their devices and rapidly get their FDA Cybersecurity Documentation in order.

What changed:

→ All CFR 820 references replaced with new QMSR citations
→ Full alignment with ISO 13485:2016 requirements now incorporated by reference
→ Tool validation requirements now referenced under QMSR 4.1.6
→ CI/CD explicitly recognized as production controls under QMSR

Why this matters: The QMSR took effect February 2, 2026, fundamentally changing how FDA regulates quality management systems. This guidance update ensures cybersecurity requirements are properly mapped to the new framework.

What you need to do: If you're preparing a 510(k), PMA, or De Novo for a cyber device, your submission documentation must now reference QMSR requirements—not the old 820 structure. Section 524B requirements remain unchanged, but the quality system foundation they rest on has shifted.

The guidance emphasizes that any device with network connectivity—including USB, Bluetooth, NFC, or internet—requires comprehensive cybersecurity documentation including threat modeling, SBOM generation, penetration testing, and risk management reports. These are still the top issues slowing down submissions.

Check out our 14 common cybersecurity deficiencies and how to address them before FDA asks → [https://hubs.li/Q041DKck0](https://hubs.li/Q041DKck0)

Or better yet, reach out to us if you're planning on submitting an upcoming 510(k), IDE, De Novo, or PMA and need help with cybersecurity documentation: [https://hubs.li/Q041DLyZ0](https://hubs.li/Q041DLyZ0)

We can help you decipher non-binding FDA Guidance and focus on what matters for what you're building.

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[\#Cybersecurity](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23qmsr&origin=HASH_TAG_FROM_FEED)
[\#QMSR](https://www.linkedin.com/search/results/all/?keywords=%23qmsr&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)

Were you looking to clarify the question of a HCPs' responsibilities with AI when automated processes lead to erroneous readings, findings, or results?

You may have missed that the [FDA](https://www.linkedin.com/company/fda/) issued CDS guidance earlier this year... and now there's a newer version (as of January 29, 2026).

If you haven't had a chance to review it but are curious about what changed, we're tracking the latest at Innolitics and keeping a tab on what matters for SaMD developers like you.

The latest Clinical Desision Support Software Guidance was marked as the final version. It defines the FDA's current regulatory approach to Clinical Decision Support (CDS) software used by health care professionals (HCPs).

The 4 Mandatory Criteria for Non-Device CDS Status:

1\. Software must not acquire, process, or analyze medical images, IVD signals, or signal patterns
2\. Software may display, analyze, or print medical information, including patient data, guidelines, and peer-reviewed literature
3\. Software may support or provide recommendations to HCPs but must not replace or direct clinical judgment
4\. Software must allow HCPs to independently review the basis of recommendations (Key Focus here)

Some more clarity has been provided. This version:

• Emphasizes transparency—plain-language descriptions of algorithms, data sources, validation, and limitations
• Notes increased risk of automation bias, especially in time-critical or high-automation scenarios
• Confirms CDS intended for patients or caregivers generally remains a regulated device
• Provides extensive examples distinguishing Non-Device CDS vs. Device software functions
• Guidance is nonbinding, reflecting FDA's current thinking, not enforceable law

The January 2026 update adds enforcement discretion for "one clinically appropriate recommendation" scenarios and clarifies what constitutes a "pattern" vs. discrete measurements. This is reducing regulatory burden for certain AI/ML tools while maintaining safety guardrails.

Want to understand the differences between the old and new guidance versions? Innolitics has created a detailed analysis with side-by-side comparisons and an interactive CDS classification tool.

Read the full breakdown: [https://hubs.li/Q041bGPr0](https://hubs.li/Q041bGPr0)

The [FDA](https://www.linkedin.com/company/fda/) recently released their 2025 CDRH Annual Report. We monitor FDA's regulatory landscape so you can focus on building. Is your regulatory strategy ready for 2026?

From 2025: 264,670 devices regulated, 21,780 submissions received, 124 novel devices authorized (one of the highest totals in CDRH's 40+ year history), 21 guidances issued.

Looking Ahead to 2026:
→ Implement QMSR (Quality Management System Regulation) which goes live February 2, 2026
→ Expand postmarket surveillance
→ Strengthen CDRH resilience: adapting to staffing changes, evolving processes, and shifting technological demands

The FDA is acknowledging resource constraints while signaling they're optimizing for high-impact work.

Innolitics Translation: FDA is prioritizing well-prepared submissions over managing deficiency cycles.

There's already an emphasis on Safety & Quality initiatives like:

→ Early Alert Pilot expanded to all device types—accelerating communication of potentially high-risk recalls
→ Cybersecurity guidance finalized: strengthening device security requirements at the design stage (We covered this in another article on our website as well)

We analyzed all 295 AI/ML clearances from our 2025 Year in Review to help you benchmark against the market:

→ Review times by specialty (radiology 71.5%, cardiovascular 8.8%)
→ SaMD vs. hardware trends (62% SaMD)
→ PCCP adoption patterns
→ The innovator landscape (221 manufacturers, 183 first-time clearances)

Full analysis: [https://hubs.li/Q0412FN60](https://hubs.li/Q0412FN60)

Reach out to us, we love to hear from our readers\!

The [FDA](https://www.linkedin.com/company/fda/)'s New Quality Management System Regulation (QMSR) Takes Effect February 2, 2026

For SaMD developers, this directly intersects with FDA's 2025 cybersecurity guidance: Cybersecurity is Part of Device Safety and the Quality System Regulation.

The QMSR incorporates ISO 13485:2016, which embeds risk management (ISO 14971\) across your entire quality system—not just product design. FDA's cybersecurity guidance clarifies that cybersecurity risks must be assessed through the same QMS framework.

Your CI/CD pipeline needs manufacturing-line rigor. Ad-hoc build processes and unvalidated deployment scripts are no longer defensible. Cybersecurity controls are now explicit quality requirements.

Development and quality tools require validation proportionate to their cybersecurity risk. Tools that could compromise device safety or quality data require comprehensive validation and security controls.

Timeline: The QMSR is effective February 2, 2026, with a 2-year transition period for manufacturers to update their quality systems.

FDA's 2025 cybersecurity guidance requires demonstrating that cybersecurity controls are integrated into design controls, validated through testing, and maintained through CAPA—all core QMSR requirements. Your SBOM, threat modeling, security architecture, and vulnerability management are now QMS compliance documentation.

📩 Learn more about how we help teams achieve FDA clearance through integrated quality systems and cybersecurity: [https://hubs.li/Q040LgmP0](https://hubs.li/Q040LgmP0))

Source: [https://hubs.li/Q040Ll-80](https://hubs.li/Q040Ll-80)

Why do clinicians still hesitate to trust your clinical AI even after FDA clearance?

A new Nature Medicine paper from leading voices in clinical AI evaluation: Tej Azad, Harlan Krumholz, and Suchi Saria of [Bayesian Health](https://www.linkedin.com/company/bayesian-health/) identifies the gap between regulatory approval and clinical adoption.

The paper propose 4 principles to transform clinical AI evaluation from benchmarks to real-world readiness:

1\. Task-specific readiness (not model-centric): Evaluate at the clinical task level—not isolated model performance. The question isn't "How accurate is the model?" but "For which specific task does this system demonstrate readiness relative to standard of care under realistic conditions?"

The FDA already recognizes this distinction. CADx decisions influence treatment pathways, requiring stronger ROC-based analytics and pathology-confirmed ground truth. CADe decisions get additional human review, so radiologist consensus suffices.

2\. Study form \= use form: Test exactly as it will be deployed, in real workflows with actual users, constraints, and failure modes.

Reader studies demonstrate whether your device actually improves diagnostic performance when radiologists use it—or whether it creates over-reliance, alert fatigue, or workflow disruption.

For triage devices, FDA goes further: prove your tool meaningfully accelerates case handling. A stroke triage algorithm needs evidence it reduces time-to-notification, not just high sensitivity on a test set.

3\. Readiness proven through use, not accuracy alone

Measure what clinicians care about: adoption rates, correction burden, time-to-action—not just standalone accuracy.

In other words, Analytical Validation asks "Does the software correctly produce its intended output?" Clinical Validation asks "Does that output achieve the intended clinical purpose?"

Quantify conversation delta (how much clinicians modify your output), deferral awareness (does your system know its limits?), and over-reliance risk.

4\. Deferral is first-class safety infrastructure

This aligns with FDA's expectation that sponsors demonstrate performance across subpopulations and edge cases. Your submission should break down accuracy by age, scanner type, lesion size, and acquisition parameters— to show you understand where your device struggles and have mitigations in place.

Innolitics Takeaway: The gap between FDA requirements and hospital procurement criteria is closing.

We've helped 70+ medical device companies design clinical validation strategies that satisfy both FDA requirements and hospital procurement committees. Our testing expectations guide breaks down exactly what FDA requires for each device type—from CADe to CADx to triage systems.

Our FDA testing expectations guide for AI/ML SaMD → [https://hubs.li/Q040xJyS0](https://hubs.li/Q040xJyS0)

Partner with Innolitics for end-to-end development and validation → [https://hubs.li/Q040xG7X0](https://hubs.li/Q040xG7X0)

Does your device connect to a hospital network or EHR?

A joint effort between ISO's Technical Committee 215 (ISO/TC 215\) and IEC's Sub-Committee 62A (IEC/SC 62A) has met this month. Joint Working Group 7 focuses on safe, effective, and secure health software and health IT systems, including medical devices: [ISO Health Informatics \[TC 215\]](https://www.linkedin.com/company/iso-health-informatics/)

The Strategic Context: [https://hubs.li/Q040m4F00](https://hubs.li/Q040m4F00)

\- Part 1 (81001-1): Foundational terminology (Published)
\- Part 4-1 (81001-4-1): Healthcare delivery organization (HDO) implementation and clinical use risk management (Work Item / Committee Draft)
\- Part 5-1 (81001-5-1): Manufacturer lifecycle security requirements (Published 2021\)

Three Strategic Implications:

1\. Scope Redefinition: The title evolution signals regulatory focus has migrated from network infrastructure to software systems and clinical workflow integration as the primary risk domain.

\- Previous: "Application of risk management for IT-networks incorporating medical devices"
\- Current: "Health software and health IT systems safety, effectiveness and security—Part 4-1: Application of risk management in the Implementation and Clinical Use"

2\. Manufacturer-HDO Interdependency:
While 81001-4-1 formally addresses HDO responsibilities, manufacturer compliance has become a critical enabler. FDA expectations increasingly require device manufacturers to provide:

\- Security capability documentation (MDS2 forms)
\- Software Bills of Materials (SBOMs)
\- Implementation guidance enabling HDO compliance with 81001-4-1

Manufacturers that fail to provide adequate security documentation create downstream HDO compliance barriers that constrain market access.

3\. Standards redesignation triggers systematic documentation updates across:

\- Quality management system procedures
\- Regulatory submission templates
\- Risk management documentation
\- Supplier quality agreements
\- Customer-facing technical specifications

At Innolitics, we've integrated IEC 81001-5-1 cybersecurity requirements across multiple FDA submissions and maintain real-time tracking of the IEC 80001 → ISO 81001 transition within our regulatory guidance infrastructure and client deliverable templates.

This proactive standards monitoring ensures submission documents reference current nomenclature, preventing avoidable regulatory review delays.

Next Steps:
Evaluate your device's security capability documentation against evolving FDA expectations → [https://hubs.li/Q040m76N0](https://hubs.li/Q040m76N0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23standards&origin=HASH_TAG_FROM_FEED)
[\#Standards](https://www.linkedin.com/search/results/all/?keywords=%23standards&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23iso81001&origin=HASH_TAG_FROM_FEED)
[\#ISO81001](https://www.linkedin.com/search/results/all/?keywords=%23iso81001&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23iec80001&origin=HASH_TAG_FROM_FEED)
[\#IEC80001](https://www.linkedin.com/search/results/all/?keywords=%23iec80001&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda510k&origin=HASH_TAG_FROM_FEED)
[\#FDA510k](https://www.linkedin.com/search/results/all/?keywords=%23fda510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[\#Cybersecurity](https://www.linkedin.com/search/results/all/?keywords=%23cybersecurity&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryStrategy](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)

Your legacy medical device software holds years of validated logic, regulatory approvals, and proprietary algorithms. Rebuilding from scratch means years of re-validation and millions in regulatory costs. Leaving it untouched means falling behind on interoperability requirements and modern standards.

Legacy systems carry another burden: cybersecurity vulnerabilities that accumulate over time. Deprecated dependencies, outdated authentication patterns, and architectures built before FDA's 2023 cybersecurity guidance all create submission risks. Modernizing your tech stack addresses these vulnerabilities while enabling the compliant interoperability that healthcare systems now require.

At Innolitics, we're deeply familiar with this exact problem space.

During our weekly 10x Engineering Discussion, we demonstrated the results of work for a client who made an unusual request: modernize their legacy codebase without using AI.

Their concern was straightforward: proprietary information leakage through LLM providers.

We've spent 14 years building medical device software across 100+ FDA submissions. Our team refactors proprietary codebases, migrates to modern tech stacks, and maintains full regulatory traceability.

With or without AI assistance.

This work requires a deep understanding of medical device software development, regulatory requirements, and legacy system architecture. AI tools offer leverage, but they cannot replace domain expertise.

When you're migrating decades-old C++ to a modern tech stack while maintaining FDA traceability and preserving complex business logic, you need engineers who understand what the code actually does, and not just how to refactor it.

A properly modernized codebase with clean architecture, comprehensive testing, and current tooling accelerates every subsequent feature release. Your team can respond to customer requests at higher velocity. New market opportunities become feasible. Product improvements that once required months of careful refactoring can be implemented in weeks with confidence.

Learn more about our approaches to AI-augmented engineering: [https://hubs.li/Q03\_YltW0](https://hubs.li/Q03_YltW0)

Reach out to see how we can address the FDA's cybersecurity concerns for legacy and modern systems: [https://hubs.li/Q03\_YlQp0](https://hubs.li/Q03_YlQp0)

Your FDA strategy could become an NIH case study.

When CorticoMetrics secured SBIR/STTR funding to develop their neuroimaging SaMD, they needed a partner who understood both cutting-edge software engineering and FDA compliance.

CorticoMetrics faced a critical bottleneck: their MATLAB-dependent FreeSurfer software was too slow for clinical use, and they needed FDA-quality documentation.

We helped them:

→ Port complex MATLAB algorithms to Python

→ Design and implement FDA-compliant architecture

→ Deliver integrated tests and 510(k)-ready documentation

→ Leverage our deep DICOM and medical imaging expertise

As their CEO put it: "Innolitics' understanding of medical imaging analysis software and FDA quality processes was key to the success of the project."

Our collaboration was so successful that the NIH published their application as a sample for other small businesses to follow. The NIH uses it to showcase best practices for small businesses seeking federal funding for medical device development

📄 See how CorticoMetrics documented their NIH-funded FDA strategy → [https://hubs.li/Q03\_CZcv0](https://hubs.li/Q03_CZcv0)

Whether you're a small business building your first medical device or an established organization breaking into the US market, we bridge the gap between world-class software engineering and FDA regulatory requirements.

📖 Read the full case study → [https://hubs.li/Q03\_C\_cq0](https://hubs.li/Q03_C_cq0)

📞 Ready to de-risk your path to clearance? → [https://hubs.li/Q03\_CZdh0](https://hubs.li/Q03_CZdh0)

What if your AI/ML-enabled medical device could gain limited market access and real-world evidence \*without\* traditional FDA clearance or approval?

Beyond BDD and STeP, the FDA's TEMPO Pilot Program offers a new pathway: enforcement discretion for select digital health technologies in key clinical domains, enabling you to test with patients under appropriate safeguards while you learn alongside regulators.

How TEMPO Differs from BDD and STeP:

Unlike Breakthrough Device Designation (BDD) or the Safer Technologies Program (STeP), which are designed to accelerate premarket clearance or approval, TEMPO is primarily a regulatory learning pilot.

In exchange, manufacturers must collect and share real-world performance data (real-world data or “RWD”) to generate real-world evidence (“RWE”) about safety, effectiveness, and patient outcomes. That data will inform later full marketing authorization submissions

The FDA has identified four clinical domains for the TEMPO pilot, selecting up to approximately 10 manufacturers per area:

• Cardio-Kidney-Metabolic (CKM) conditions: cardiovascular disease, diabetes, chronic kidney disease, obesity-related conditions
• Musculoskeletal conditions: orthopedic, rehabilitation, mobility-related technologies
• Behavioral health conditions: mental health, substance use disorders, neurobehavioral conditions
Additional specific cardiovascular domains: referenced separately from broader CKM conditions in FDA program materials

🔗 TEMPO Program details: [https://hubs.ly/Q03\_xtMB0](https://hubs.ly/Q03_xtMB0)

Navigating FDA's evolving program landscape: like the TEMPO Program, BDD, STeP, and traditional pathways requires strategic clarity on which route best serves your device's clinical profile and market goals.

Learn more about FDA's Breakthrough Device and STeP Programs to compare your regulatory strategy options: [https://hubs.ly/Q03\_xrdB0](https://hubs.ly/Q03_xrdB0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23tempo&origin=HASH_TAG_FROM_FEED)
[\#TEMPO](https://www.linkedin.com/search/results/all/?keywords=%23tempo&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryscience&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryScience](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryscience&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevice](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)

We're excited to announce our new Innolitics 510(k) Analyzer tool. This tool makes FDA 510(k) submissions easier to understand and analyze. It's a complementary tool to our new Innolitics 510(k) Search Engine on the FDA's openFDA Community page.

The Innolitics 510(k) Analyzer provides page-by-page AI-powered analysis of FDA submissions, extracting key insights, validation strategies, and regulatory patterns that would otherwise take hours to identify manually.

Check out our analysis of K252366 (a2z-Unified-Triage). This radiological triage device detects 7 critical findings in abdominal/pelvic CT scans and includes a PCCP for continuous improvement. It's a blueprint for how modern AI medical devices will get cleared.

📍 Try the 510(k) Analyzer: [https://hubs.li/Q03-G3fD0](https://hubs.li/Q03-G3fD0)

📍 or visit the example 510(k) analysis of the a2z-Unified-Triage: [https://hubs.li/Q03-GdSP0](https://hubs.li/Q03-GdSP0)

📍 Read the deep-dive on K252366: [https://hubs.li/Q03-G3HR0](https://hubs.li/Q03-G3HR0)

Our goal is to make regulatory intelligence accessible and actionable. Whether you're a device manufacturer, regulatory professional, or competitor analyzing the landscape, our tool helps you understand what FDA is clearing and why.

This tool was built by Innolitics, a team of medical device software developers specializing in AI/ML SaMD, FDA regulatory strategy, DICOM, ISO62304, and medical imaging. If this tool is useful to you or you have suggestions for improvement, please reach out as we'd love to hear your thoughts\!

Contact Innolitics to ensure your AI/ML Software as a Medical Device is cleared efficiently.

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23artificialintelligence&origin=HASH_TAG_FROM_FEED)
[\#ArtificialIntelligence](https://www.linkedin.com/search/results/all/?keywords=%23artificialintelligence&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)

🤔 There is a lot of hype around the new CDS and Wellness guidances. However, when you do a side-by-side comparison to the previous versions and dissect the mental model of FDA from first principles, I don't think much has changed actually.

FDA’s 2026 guidances for Clinical Decision Support (CDS) and General Wellness are mostly clarifications, not a revolution. But the two real changes are significant for digital health builders.

Here’s the big picture:

➡️ The Two Carve-Outs: FDA’s goal is to focus on high-risk products. They’ve created two main paths to stay off their radar: General Wellness (low-risk, lifestyle products) and Non-Device CDS (for HCPs, with reviewable logic).

➡️ The Regulatory Map: Your path is determined by two simple questions: Who is the user (Patient vs. HCP)? And what is the intended use (Lifestyle vs. Disease)? Answering this defines your territory.

➡️ What Stayed the Same: Most of the guidances just clarified existing rules. The definition of a “pattern” didn’t change, wellness still means low-risk, and your UI/marketing continues to define your intended use.

➡️ What Actually Changed: Two key shifts happened. FDA introduced enforcement discretion for when there’s only “one clinically appropriate option,” and they created a structured pathway for non-invasive wellness biometric sensors.

➡️ FDA’s Mental Model: The agency operates on a simple 2x2: Risk vs. Interpretability. Your goal is to design products for the “Easy to Interpret, Low Risk” quadrant. That’s where FDA steps back.

➡️ The 5 Design Levers: You have five levers to control your regulatory burden: Intended User, Input Type, Output Style, Reviewability, and UI/Marketing. Use them wisely.

Read the full article here: [https://hubs.li/Q03-cN3b0](https://hubs.li/Q03-cN3b0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatory&origin=HASH_TAG_FROM_FEED)
[\#Regulatory](https://www.linkedin.com/search/results/all/?keywords=%23regulatory&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23healthtech&origin=HASH_TAG_FROM_FEED)
[\#HealthTech](https://www.linkedin.com/search/results/all/?keywords=%23healthtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23cds&origin=HASH_TAG_FROM_FEED)
[\#CDS](https://www.linkedin.com/search/results/all/?keywords=%23cds&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[\#AIinHealthcare](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevice&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevice](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevice&origin=HASH_TAG_FROM_FEED)

📢 We are live on openFDA\!

We are excited to announce that the Innolitics 510(k) Search Engine is now officially listed on the FDA’s openFDA Community page.

Our goal has always been to make regulatory intelligence accessible and actionable. With our tool, you can slice through 510(k) data with precision and filter by Product Code (like QIH), intended and decision dates to visualize trends instantly.

Why this matters: finding the right predicate device is the foundation of a successful submission.

📍 Check us out on the FDA website: [https://hubs.li/Q03Zwcwz0](https://hubs.li/Q03Zwcwz0)
📍 Try the tool directly: [https://hubs.li/Q03Zw9yl0](https://hubs.li/Q03Zw9yl0)

Navigating the data is step one. Getting your SaMD cleared is step two. Contact Innolitics today to ensure your Software as a Medical Device is cleared in a timely manner.

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23openfda&origin=HASH_TAG_FROM_FEED)
[\#OpenFDA](https://www.linkedin.com/search/results/all/?keywords=%23openfda&origin=HASH_TAG_FROM_FEED)

When Requirements Are Too Small

⚠️ Everyone talks about requirements being too large, but what about too small?

Examples we see:

REQ-1: The system must have a login page.
REQ-2: The login page must have a username field.
REQ-3: The login page must have a password field.
REQ-4: The login page must have a submit button.
REQ-5: The login page must validate credentials.

This creates excessive verification overhead.

Five separate test protocols for what should be one cohesive login function.

Better approach:

REQ-1: The system must authenticate users via username and password.
REQ-2: The system must reject invalid credentials with an error message.
REQ-3: The system must grant access only to users with valid credentials.

The balance:

Requirements should be: → Small enough to verify independently
→ Large enough to describe meaningful functionality
→ Focused on WHAT the system should do, not HOW it looks

Pro tip: If your requirement describes user interface (UI) layout rather than functionality, it's probably too granular.

📖 Discover our requirement practices that help us submit FDA applications in record time: [https://hubs.li/Q03MP-ZM0](https://hubs.li/Q03MP-ZM0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23softwaredevelopment&origin=HASH_TAG_FROM_FEED)
[\#SoftwareDevelopment](https://www.linkedin.com/search/results/all/?keywords=%23softwaredevelopment&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23qualityassurance&origin=HASH_TAG_FROM_FEED)
[\#QualityAssurance](https://www.linkedin.com/search/results/all/?keywords=%23qualityassurance&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23requirements&origin=HASH_TAG_FROM_FEED)
[\#Requirements](https://www.linkedin.com/search/results/all/?keywords=%23requirements&origin=HASH_TAG_FROM_FEED)

🤯Just published\! This could be HUGE for AI/ML SaMD. FDA is evaluating a petition requesting partial exemption of certain AI/ML from 510(k). Here are thoughts:

This reminds me back when the prior Trump administration tried to make the devices 510(k) exempt entirely.

However, in this case, it is a "partial exemption"

This applies to product codes POK, MYN, QAS, QFM, and QDQ. Which includes CADt, CADe, and CADx

Curiously, QIH is missing from that list.

In a nutshell, the petition is saying that once a manufacturer gets cleared for the regulation, they don't have to come back to FDA for subsequent devices under the same regulation, provided the manufacturer abides by post-market, training, and transparency as described in the petition.

More on that later.

Note that this is still in the public comment phase, so it is not final. I expect there to be a lot of discourse on this topic.

A couple of immediate thoughts:
1\. This petition was filed by [Harrison.ai](https://www.linkedin.com/company/harrison-ai/)

2\. It essentially allows manufacturers to more easily get pre-cleared for an entire platform and portfolio of algorithms instead of just one.

3\. It will probably make the predetermined change control plan obsolete for the aforementioned product codes.
4\. It reminds me of the software pre-certification program that unfortunately never went through.
5\. It will give a huge advantage for manufacturers that already have products cleared under these product codes.

I think this is even more important to get your device FDA cleared and get it done today so that if this eventually becomes a rule of law then your company will be ready to release a portfolio of algorithms.

We can help you get there: [https://hubs.ly/Q03Z6cV90](https://hubs.ly/Q03Z6cV90)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fdaclearance&origin=HASH_TAG_FROM_FEED)
[\#FDAClearance](https://www.linkedin.com/search/results/all/?keywords=%23fdaclearance&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23clinicalai&origin=HASH_TAG_FROM_FEED)
[\#ClinicalAI](https://www.linkedin.com/search/results/all/?keywords=%23clinicalai&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicalimagingai&origin=HASH_TAG_FROM_FEED)
[\#MedicalImagingAI](https://www.linkedin.com/search/results/all/?keywords=%23medicalimagingai&origin=HASH_TAG_FROM_FEED)

⚡Interested in seeing how other successful organizations have conducted their MRMC and Standalone studies? Here's how DeepHealth used Special 510(k) for Saige-Dx expansion.

Original Clearance: K220105 (Traditional 510(k))

MRMC Study:

1\. 18 MQSA readers
2\. 240 cases
3\. ≥4-week washout

Standalone Study:

1\. 1,304 cases
2\. 9 U.S. sites
3\. The Evolution: K251873 (Special 510(k), 2025\)

New Standalone Study:

1\. 2,002 DBT mammograms
2\. Multi-vendor: Hologic & GE
3\. Non-inferiority vs predicate (K243688)
4\. Prior MRMC evidence remained applicable

The strategic brilliance:

1\. Used Special 510(k) pathway for manufacturer expansion
2\. Leveraged existing MRMC data
3\. Only needed fresh Standalone for new vendors
4\. Ongoing standalone accrual enabled this fast modification

The lesson: Initial clearance: Both MRMC \+ Standalone Future expansions:

Standalone only (when MRMC precedent exists)

This is how you build modular regulatory strategy. One MRMC. Multiple Standalone
expansions.

🔗 See the complete Special 510(k) framework: [https://hubs.li/Q03NCMC\_0](https://hubs.li/Q03NCMC_0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23mammography&origin=HASH_TAG_FROM_FEED)
[\#Mammography](https://www.linkedin.com/search/results/all/?keywords=%23mammography&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23clinicalai&origin=HASH_TAG_FROM_FEED)
[\#ClinicalAI](https://www.linkedin.com/search/results/all/?keywords=%23clinicalai&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fdaclearance&origin=HASH_TAG_FROM_FEED)
[\#FDAClearance](https://www.linkedin.com/search/results/all/?keywords=%23fdaclearance&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryStrategy](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)

The Requirement That Should Never Be Written

🚫 We see this in almost every Software Requirements Specification (SRS):

"The system must be developed in compliance with FDA 21 CFR 820.30."

This is not a requirement.

21 CFR 820.30 describes THE PROCESS you use to develop the device, not a characteristic of the device itself.

Can you TEST whether the software complies with 820.30?

No. You verify 820.30 compliance by reviewing DHF documentation, not by testing
the software.

Other pseudo-requirements we see:
❌ "The system must be developed following IEC 62304"

❌ "The software must be designed using Agile methodology"

❌ "Development must follow our Quality Management System"

Why this creates problems:
→ Unverifiable through testing
→ Redundant with your DHF
→ Gives FDA reviewers extra questions to ask

What to do instead:
Let your DHF demonstrate process compliance. Keep requirements focused on what the PRODUCT must do.

The exception:
If a regulation specifies product characteristics (like multi-factor authentication), reference the specific requirement:

✅ "The system must support multi-factor authentication per FDA Cybersecurity Guidance Section 3.2."

Not: ❌ "The system must comply with FDA Cybersecurity Guidance."

📖 Learn how we write requirements that accelerate FDA submissions: [https://hubs.li/Q03MPV9B0](https://hubs.li/Q03MPV9B0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23qualitymanagement&origin=HASH_TAG_FROM_FEED)
[\#QualityManagement](https://www.linkedin.com/search/results/all/?keywords=%23qualitymanagement&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23designcontrols&origin=HASH_TAG_FROM_FEED)
[\#DesignControls](https://www.linkedin.com/search/results/all/?keywords=%23designcontrols&origin=HASH_TAG_FROM_FEED)

Picture Archiving and Communication Systems (PACS) received 14 AI/ML clearances in 2025\.

The infrastructure of medical imaging is getting an intelligence upgrade.

PACS systems are the backbone of medical imaging workflows, storing and distributing images across healthcare systems.

AI integration is adding: → Intelligent routing → Automated prioritization → Embedded diagnostic assistance → Workflow optimization

This makes the entire imaging workflow smarter, not just individual devices.

The infrastructure is becoming intelligent.

Learn how AI is transforming imaging infrastructure. 👇

[https://hubs.li/Q03YPp1m0](https://hubs.li/Q03YPp1m0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23pacs&origin=HASH_TAG_FROM_FEED)
[\#PACS](https://www.linkedin.com/search/results/all/?keywords=%23pacs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicalimaging&origin=HASH_TAG_FROM_FEED)
[\#MedicalImaging](https://www.linkedin.com/search/results/all/?keywords=%23medicalimaging&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23healthcareit&origin=HASH_TAG_FROM_FEED)
[\#HealthcareIT](https://www.linkedin.com/search/results/all/?keywords=%23healthcareit&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23imagingworkflow&origin=HASH_TAG_FROM_FEED)
[\#ImagingWorkflow](https://www.linkedin.com/search/results/all/?keywords=%23imagingworkflow&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23healthcareai&origin=HASH_TAG_FROM_FEED)
[\#HealthcareAI](https://www.linkedin.com/search/results/all/?keywords=%23healthcareai&origin=HASH_TAG_FROM_FEED)

What if you could update your cleared AI/ML model without a new FDA submission for every change?

That's the power of a Predetermined Change Control Plan (PCCP).

And 10% of cleared devices in 2025 are already using it.

PCCPs are a game-changer for the industry.

This innovative framework allows manufacturers to get pre-authorization for future modifications, enabling rapid, iterative improvement of algorithms.

As AI models continuously learn and improve, the PCCP pathway provides a regulatory framework that keeps pace with the technology—ensuring patients have access to the most up-to-date solutions.

Why PCCPs matter: → Pre-authorized future modifications → Faster iteration cycles → Continuous algorithm improvement → Regulatory agility

Is a PCCP right for your device? Learn more about this agile regulatory framework. 👇

[https://hubs.li/Q03YPnLC0](https://hubs.li/Q03YPnLC0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23pccp&origin=HASH_TAG_FROM_FEED)
[\#PCCP](https://www.linkedin.com/search/results/all/?keywords=%23pccp&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fdaregulatory&origin=HASH_TAG_FROM_FEED)
[\#FDARegulatory](https://www.linkedin.com/search/results/all/?keywords=%23fdaregulatory&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[\#AIinHealthcare](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryinnovation&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryInnovation](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryinnovation&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)

IEC 62304 Says You Need These Requirements

📋 Every SaMD team asks: "What requirements do we actually need?"

IEC 62304 gives you the answer. Here's the checklist:

1\. Functional and capability requirements
2\. Performance (purpose of software, timing requirements)
3\. Physical characteristics (code language, platform, OS)
4\. Computing environment (hardware, memory, network)
5\. Software inputs and outputs
6\. Data characteristics (format, ranges, limits, defaults)
7\. Interfaces with other systems
8\. Alarms, warnings, and operator messages
9\. Security requirements
10 .User interface requirements
11 .Database requirements
12 .Installation and acceptance requirements
13 .Operation and maintenance methods
14 .IT network aspects
15 .User maintenance requirements
16 .Regulatory requirements
Common gaps we see:

❌ "What happens when the network drops mid-procedure?"

❌ "What's the minimum RAM needed?"

❌ "How do users know the system is processing vs. frozen?"

Pro tip: Use this as a checklist during requirements review. Not every category applies to every device, but you should at least CONSIDER each one.

📖 See how we use IEC 62304 to streamline our FDA submission process: [https://hubs.li/Q03MPTf40](https://hubs.li/Q03MPTf40)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23iec62304&origin=HASH_TAG_FROM_FEED)
[\#IEC62304](https://www.linkedin.com/search/results/all/?keywords=%23iec62304&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23softwareengineering&origin=HASH_TAG_FROM_FEED)
[\#SoftwareEngineering](https://www.linkedin.com/search/results/all/?keywords=%23softwareengineering&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23compliance&origin=HASH_TAG_FROM_FEED)
[\#Compliance](https://www.linkedin.com/search/results/all/?keywords=%23compliance&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23standards&origin=HASH_TAG_FROM_FEED)
[\#Standards](https://www.linkedin.com/search/results/all/?keywords=%23standards&origin=HASH_TAG_FROM_FEED)

The MAUDE Database Trick for Finding Missing Requirements

🔍 Here's a free resource that reveals requirements you never thought of:

The MAUDE Database (FDA's adverse event reports)

How to use it:

Search MAUDE for your device's product code

Filter for adverse events in the last 5 years

Look for patterns

What you'll find:

"Device failed to alert when battery was low" → Need battery warning requirement

"Software crashed with special characters in patient name" → Need input validation
requirements

"Device lost WiFi mid-procedure with no indication" → Need connection status requirements

Real example:

A client building diagnostic imaging found incidents where similar devices:

Exported images in the wrong orientation

Lost calibration data after a power cycle

Displayed corrupted images on certain monitors

None were in their original requirements.

Time investment: 2-4 hours

Requirements identified: Usually 10-20

Field failures avoided: Priceless

Start your own search here: [https://hubs.li/Q03MPJkW0](https://hubs.li/Q03MPJkW0)

📖 Learn our complete method for bulletproof requirements that accelerate FDA submission: [https://hubs.li/Q03MPFMz0](https://hubs.li/Q03MPFMz0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23riskmanagement&origin=HASH_TAG_FROM_FEED)
[\#RiskManagement](https://www.linkedin.com/search/results/all/?keywords=%23riskmanagement&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23patientsafety&origin=HASH_TAG_FROM_FEED)
[\#PatientSafety](https://www.linkedin.com/search/results/all/?keywords=%23patientsafety&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23productdevelopment&origin=HASH_TAG_FROM_FEED)
[\#ProductDevelopment](https://www.linkedin.com/search/results/all/?keywords=%23productdevelopment&origin=HASH_TAG_FROM_FEED)

GitHub Issues Are Not Requirements (Usually)

⚠️ "Can we just use our GitHub Issues as requirements for FDA submission?"

Short answer: Technically yes, but we don't recommend it.

The problem:

Issue \#403: "Add patient export feature"

Issue \#892: "Update patient export to include lab results"

Issue \#1205: "Fix: patient export crashes on empty records"

Which of these are the current requirements?

Issue trackers track CHANGES, not CURRENT STATE.

This creates problems:

→ Version confusion \- Which closed issues are still valid?

→ Contradictions \- Issue \#892 partially overrides \#403

→ Scope creep \- Every bug becomes part of your requirements

→ FDA questions \- "Why was requirement \#1205 necessary?"

What we recommend:

Use GitHub Issues for the development workflow.

But maintain a separate, clean SRS that represents CURRENT requirements.

Think of it: GitHub Issues \= the journey, SRS \= the destination

📖 Discover how we organize requirements for rapid FDA submissions: [https://hubs.li/Q03MPDnh0](https://hubs.li/Q03MPDnh0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23softwaredevelopment&origin=HASH_TAG_FROM_FEED)
[\#SoftwareDevelopment](https://www.linkedin.com/search/results/all/?keywords=%23softwaredevelopment&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23agile&origin=HASH_TAG_FROM_FEED)
[\#Agile](https://www.linkedin.com/search/results/all/?keywords=%23agile&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23devops&origin=HASH_TAG_FROM_FEED)
[\#DevOps](https://www.linkedin.com/search/results/all/?keywords=%23devops&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)

Most FDA‑cleared AI/ML devices still treat basic evidence reporting as optional.

A recent review of \~950 AI/ML‑enabled medical devices found that:

• 93% did not report their training data source
• 76% did not report their test data source
• Only 9–10% reported training dataset size
• Only 23% reported test dataset size
• Only 24% reported any dataset demographics
• More than 50% did not report performance metrics at all

If you are a clinician, buyer, or regulator, that makes it hard to answer basic questions:

• Who was this tested on?
• What data did the model actually see?
• How well does it perform in populations that look like mine?

At Innolitics, we have tried to push in the opposite direction.

We analyzed hundreds of AI/ML 510(k)s and extracted thousands of performance metrics and acceptance‑criteria instances across real submissions – sensitivity, specificity, AUROC, Dice, HD95, Kappa, Bland–Altman limits of agreement, and more.

👉 Read it here: [https://hubs.li/Q03Wz5-w0](https://hubs.li/Q03Wz5-w0)

Then we turned that into a practical playbook for sponsors who want their evidence package to be both realistic and regulator‑defensible.

If you are planning an AI/ML SaMD submission, you do not have to guess:

• Which metrics FDA sees most often for devices like yours
• Where to start your thresholds for sensitivity, specificity, AUC, Dice, etc.
• How to justify your acceptance criteria using predicates, special controls, and guidance

The bar for transparency is going up. Teams that treat dataset reporting and performance metrics as first‑class citizens – not afterthoughts – will have an easier time with FDA and with clinical adoption.

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[\#AIinHealthcare](https://www.linkedin.com/search/results/all/?keywords=%23aiinhealthcare&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicalimagingai&origin=HASH_TAG_FROM_FEED)
[\#MedicalImagingAI](https://www.linkedin.com/search/results/all/?keywords=%23medicalimagingai&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)

The FDA just announced it’s rolling out agentic AI tools to all FDA employees – including reviewers, scientists, and investigators (source link in the comments)

In plain terms: your next SaMD submission is more likely to be reviewed by a human \*plus\* AI.

That’s good news if your documentation is consistent and traceable. It’s risky if your design inputs, risk management, verification, and clinical evidence all tell slightly different stories.

What does this mean for you:

• Review speed may improve, but so will scrutiny: Sloppy traceability or copy‑pasted rationales will be easier to flag.
• Lifecycle narrative matters more: FDA’s own AI, Elsa, will help reviewers reason about your data governance, model changes, PCCPs, and post‑market monitoring.
• Inconsistencies will get expensive: Fixing issues after a deficiency letter, when FDA is moving faster, will hurt timelines even more.

At Innolitics, we’re already helping AI/ML teams prepare for an FDA that uses AI itself:

• Translating announcement and guidance like this into concrete requirements for design inputs, risk files, validation, and submission structure
• Using our in-house Notion-based MedtechOS to keep regulatory strategy, templates, risks, and evidence aligned so teams can move quickly without losing coherence

If you’re building AI/ML SaMD and wondering what agentic AI at FDA means for your roadmap and submissions, we’re happy to walk through it\!

🔗 See how MedtechOS supports AI/ML regulatory projects day‑to‑day: [https://hubs.li/Q03WmCT80](https://hubs.li/Q03WmCT80)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[\#SaMD](https://www.linkedin.com/search/results/all/?keywords=%23samd&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23aiml&origin=HASH_TAG_FROM_FEED)
[\#AIML](https://www.linkedin.com/search/results/all/?keywords=%23aiml&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryAffairs](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryaffairs&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#DigitalHealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23airegulation&origin=HASH_TAG_FROM_FEED)
[\#AIRegulation](https://www.linkedin.com/search/results/all/?keywords=%23airegulation&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtechos&origin=HASH_TAG_FROM_FEED)
[\#MedtechOS](https://www.linkedin.com/search/results/all/?keywords=%23medtechos&origin=HASH_TAG_FROM_FEED)

Don't Put Business Needs in Your FDA Submission

🎯 Quick tip that can save you months of FDA review:

Keep business needs OUT of your design inputs.

"But we need to minimize device cost\!" — Yes, you do. But the FDA doesn't care.

Business needs ≠ User needs

Business need: "Minimize manufacturing costs"

User need: "Physicians need results delivered quickly."

Why this matters:
Including business needs in FDA submissions creates unnecessary review surface area.

Every requirement in your submission is something the FDA can question.

Business requirements often lead to questions about: → Cost tradeoffs
→ Market positioning → Competitive analysis → Manufacturing constraints

None of which help get your device cleared.

The fix:
Track business needs internally (yes, they're important\!)
Derive design inputs from USER needs
Submit only the user-focused requirements to the FDA

Example:
❌ DON'T submit: "The device must use off-the-shelf components to reduce costs."
✅ DO submit: "The device must have a bill of materials under $500." (if this truly affects users)

Or better yet, just don't mention cost constraints at all unless they directly impact clinical performance or user needs.

Less documentation \= fewer questions \= faster clearance.

📖 Discover our strategy for streamlined FDA submissions: [https://hubs.li/Q03VL-Jn0](https://hubs.li/Q03VL-Jn0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)
[\#RegulatoryStrategy](https://www.linkedin.com/search/results/all/?keywords=%23regulatorystrategy&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23productmanagement&origin=HASH_TAG_FROM_FEED)
[\#ProductManagement](https://www.linkedin.com/search/results/all/?keywords=%23productmanagement&origin=HASH_TAG_FROM_FEED)

Why Your UI Mockups Might Not Be Requirements

🎨 Should you include UI mockups in your Software Requirements Specification (SRS)?

The answer: It depends.

The 2023 FDA Software Guidance allows it. But just because you CAN doesn't mean you SHOULD.

The trap:

Over-specifying UI creates a verification burden AND limits design flexibility.

Every time you tweak button color or spacing, you technically need to update requirements and re-verify.

Two approaches:

Approach 1: Include mockups in SRS with flexible verification (allows reasonable variation)

Approach 2: Treat mockups as design outputs, write functional requirements instead

Pro tip: Write requirements for WHAT the UI must accomplish, not HOW it should look.

"The system must display all active alerts on the dashboard" ✅

"The dashboard must show alerts in red boxes, 300px wide, aligned top-right" ❌

📖 See how we approach design inputs to accelerate FDA submission: [https://hubs.li/Q03V6rWK0](https://hubs.li/Q03V6rWK0)

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23uxdesign&origin=HASH_TAG_FROM_FEED)
[\#UXDesign](https://www.linkedin.com/search/results/all/?keywords=%23uxdesign&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[\#MedicalDevices](https://www.linkedin.com/search/results/all/?keywords=%23medicaldevices&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23softwaredevelopment&origin=HASH_TAG_FROM_FEED)
[\#SoftwareDevelopment](https://www.linkedin.com/search/results/all/?keywords=%23softwaredevelopment&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#MedTech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23productdesign&origin=HASH_TAG_FROM_FEED)
[\#ProductDesign](https://www.linkedin.com/search/results/all/?keywords=%23productdesign&origin=HASH_TAG_FROM_FEED)

AI models can perform impressively in validation, but the hard part is making them reliable, trusted, and invisible in a working radiology workflow.

Elanchezian Somasundaram, Associate Director Children’s AI Imaging Research Center at Cincinnati Children’s Hospital Medical Center draws from personal pediatric deployments, arguing that the biggest risks live in operations and integration, and not in the algorithms themselves.

• Real-world validation exposes gaps that benchmarks miss: population differences, protocol changes, and rare edge cases.
• Robust ops matter as much as the model: clean DICOM metadata, protocol consistency, CI/CD, and continuous monitoring tied to equipment and workflow signals.
• Success is measured by reduced cognitive load: only surface results when they’re reliable and fit naturally into reading flows.
• The stack needs a rethink: PACS, RIS, and dictation weren’t built for interactive, AI-first use; open standards and community-driven platforms like MONAI Deploy and OHIF point the way forward.

The three challenges Elanchezian highlights on:

• Adaptability: “One-size-fits-all” fails across patient populations, scanners, and protocols (especially in pediatrics). This implies that models and UX must flex across study types and reader preferences, from overlays to quantitative outputs.

• Trust: Earned with operational rigor, standardized data paths, automated deployments, and drift monitoring that connects equipment QC, model signals, and clinician feedback loops. This ensures reliability holds up after go-live.

• Integration: Tacking AI onto legacy systems adds clicks and fatigue. Clinicians need an AI-aware “operating system” for radiology that cleanly routes studies, triggers models, and returns actionable results inside the reading experience.

How this looks when it ships: RadUnity, an FDA‑cleared DICOM workflow engine, maps incoming CT studies to preconfigured processing profiles, standardizes image presentation, and streamlines radiologist workflows—backed by end‑to‑end engineering, validation, and 510(k) clearance.

• Automatic DICOM routing and metadata mapping
• Configurable profiles for consistent reconstructions
• Modern UI for visibility and control

See this approach in action: check out our success story in standardizing CT workflows at scale: [https://hubs.li/Q03TpJN20](https://hubs.li/Q03TpJN20)

On the road to
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23rsna2025&origin=HASH_TAG_FROM_FEED)
[\#RSNA2025](https://www.linkedin.com/search/results/all/?keywords=%23rsna2025&origin=HASH_TAG_FROM_FEED), we wanted to share recently released, open-source CDRH/FDA
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryscience&origin=HASH_TAG_FROM_FEED)
[\#regulatoryscience](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryscience&origin=HASH_TAG_FROM_FEED) tools to help with medical imaging software development

Image Quality & Safety:

• sFRC: Detect when AI "hallucinates" fake structures in medical images \- critical for ensuring your AI reconstruction algorithms don't add or remove anatomical features that aren't really there
\[Source: [https://hubs.li/Q03TxF2v0](https://hubs.li/Q03TxF2v0)

• M-SYNTH: Test mammography AI performance across 45,000 synthetic breast images with varying densities, lesion sizes, and radiation doses \- perfect for pre-submission testing without needing large patient datasets
\[Source: [https://hubs.li/Q03TxDxk0](https://hubs.li/Q03TxDxk0)

Digital Pathology:

• SegVal-WSI: Validate how accurately your AI segments tumors vs normal tissue in gigapixel pathology slides \- essential for cancer detection algorithms:
\[Source: [https://hubs.li/Q03TxFRL0](https://hubs.li/Q03TxFRL0)

• ValidPath: Convert whole slide images to ML-ready patches, then map AI predictions back to the original slide for pathologist review in ImageScope
\[Source: [https://hubs.li/Q03TxCbQ0](https://hubs.li/Q03TxCbQ0)

Fairness & Generalization:

• [https://hubs.li/Q03TxFVD0](https://hubs.li/Q03TxFVD0): Compare different bias mitigation strategies to ensure your AI performs equitably across patient demographics \- includes visualization tools for FDA submissions
\[Source: [https://hubs.li/Q03TxG2K0](https://hubs.li/Q03TxG2K0)

• DRAGen: Test if your AI will fail on new patient populations by analyzing decision space composition \- catch generalization issues before clinical deployment
\[Source: [https://hubs.li/Q03TxF520](https://hubs.li/Q03TxF520)

• DomID: Discover hidden patient subgroups in your data that your AI might be treating differently \- uses deep clustering to find unannotated patterns
\[Source: [https://hubs.li/Q03TxDzz0](https://hubs.li/Q03TxDzz0)

Clinical Impact:

• QuCAD: Simulate how much time your triage AI actually saves in real emergency departments \- quantify clinical benefit for FDA submissions
\[Source: [https://hubs.li/Q03TxGLF0](https://hubs.li/Q03TxGLF0)

• VICTRE: Run complete virtual clinical trials for mammography/DBT devices including dose calculations \- test device changes without patient exposure
\[Source: [https://hubs.li/Q03TxFHt0](https://hubs.li/Q03TxFHt0)

Learn how to use these tools to implement best practices here: [https://hubs.li/Q03TxGMz0](https://hubs.li/Q03TxGMz0)

📚 Full catalog here: [https://hubs.li/Q03TxCJk0](https://hubs.li/Q03TxCJk0)

These tools help demonstrate safety, effectiveness, and clinical benefit for FDA submissions \- all open-source and peer-reviewed.

[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[\#FDA](https://www.linkedin.com/search/results/all/?keywords=%23fda&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[\#medtech](https://www.linkedin.com/search/results/all/?keywords=%23medtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[\#digitalhealth](https://www.linkedin.com/search/results/all/?keywords=%23digitalhealth&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23airegulation&origin=HASH_TAG_FROM_FEED)
[\#AIregulation](https://www.linkedin.com/search/results/all/?keywords=%23airegulation&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23healthtech&origin=HASH_TAG_FROM_FEED)
[\#healthtech](https://www.linkedin.com/search/results/all/?keywords=%23healthtech&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[\#510k](https://www.linkedin.com/search/results/all/?keywords=%23510k&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23denovo&origin=HASH_TAG_FROM_FEED)
[\#DeNovo](https://www.linkedin.com/search/results/all/?keywords=%23denovo&origin=HASH_TAG_FROM_FEED)
[hashtag](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryscience&origin=HASH_TAG_FROM_FEED)
[\#regulatoryscience](https://www.linkedin.com/search/results/all/?keywords=%23regulatoryscience&origin=HASH_TAG_FROM_FEED)
